The effect of thymoquinone on cell proliferation, 8-hydroxy-2 -deoxyguanosine level and expression changes of DNA repair and oxidative stress-related genes in MCF-7 breast cancer cells
Öz
Purpose: The aim of this study was to determine the effects of thymoquinone on cell proliferation, 8-hydroxy-2' -deoxyguanosine level and expression changes of oxidative stress and DNA repair-related genes in MCF-7 breast cancer cells.
Material methods: Cell proliferation in MCF-7 cells after thymoquinone exposure was determined by MTT assay. 8-hydroxy-2' -deoxyguanosine protein concentration was measured by ELISA assay. Total RNA isolation from control and thymoquinone treated cell was performed by Trizol and cDNA was synthesized. mRNA expression changes of OGG1, NEIL-1, CRCC1 SOD2, CAT and NRF-2 were also determined in RT-PCR using SYBER Green method.
Results: In this study, the IC50 dose of thymoquinone in MCF-7 cells was determined as 7.867 μM at 24th hour. It was investigated that thymoquinone inhibited 8-hydroxy-2' -deoxyguanosine level in breast cancer cells according to RT-PCR results, thymoquinone increased XRRC1 expression 4.71-fold and catalase expression 6.68-fold in breast cancer cells.
Conclusion: In conclusion, TQ inhibits MCF-7 cell proliferation under in vitro conditions. It also alters the expression of genes associated with DNA repair and oxidative stress and acts through this oxidative stress mechanism. This study contributes to the existing literature and provides preliminary data for more comprehensive studies.
Anahtar Kelimeler
Thymoquinone, MCF-7 cells, breast cancer, DNA repair genes, oxidative stress
Kaynakça
- 1. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21(11):1142-1147. doi:10.1158/1541-7786.MCR-23-0411
- 2. Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: molecular mechanisms and clinical perspectives. Pharmacol Ther. 2023;250:108522. doi:10.1016/j.pharmthera.2023.108522 3. Park JH, Pyun WY, Park HW. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. 2020;9(10):2308. doi:10.3390/cells9102308
- 4. Zhang S, Xiao X, Yi Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024;9(1):149. doi:10.1038/s41392-024-01848-7
- 5. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
- 6. Maroufi NF, Ashouri N, Mortezania Z, et al. The potential therapeutic effects of melatonin on breast cancer: an invasion and metastasis inhibitor. Pathol Res Pract. 2020;216(10):153226. doi:10.1016/j.prp.2020.153226
- 7. Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin. 2018;13(3):339-354. doi:10.1016/j.cpet.2018.02.006
- 8. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3:7. doi:10.1038/s41392-017-0004-3
- 9. Shabani H, Karami MH, Kolour J, et al. Anticancer activity of thymoquinone against breast cancer cells: mechanisms of action and delivery approaches. Biomed Pharmacother. 2023;165:114972. doi:10.1016/j.biopha.2023.114972
- 10. Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175. doi:10.1038/s41392-024-01856-7
- 11. Nahata A. Anticancer agents: a review of relevant information on important herbal drugs. Int J Clin Pharmacol Toxicol. 2017;6(2):250-255. doi:10.19070/2167-910x-1700042
